FDA Brief

Warning letters Food

FDA warning letter to

Great Healthworks, Inc.

LowIssued Jun 23, 2021Posted Jun 29, 2021Office of Human and Animal Food Operations, Division IV East

FDA warned Great Healthworks that website claims make ProbioticXL and OmegaXL unapproved drugs and ProbioticXL a misbranded food.

What happened

In May 2021, FDA reviewed the company’s website and found it took orders there for ProbioticXL and OmegaXL. FDA said website claims that the products treat, prevent, or reduce disease—such as joint pain from inflammation and cardiovascular risk factors—make them unapproved new drugs. FDA also said ProbioticXL’s unauthorized heart-disease risk claims make it a misbranded food.

What FDA found

  1. FDA says ProbioticXL’s website claims—such as fighting harmful bacteria, inhibiting yeast, reducing abdominal pain, protecting the intestinal barrier, and easing inflammation—are disease-treatment claims, making it an unapproved new drug.

    section 201(g)(1)(B) and 201(p) of the Act [21 U.S.C. 321(g)(1)(B), 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  2. FDA says OmegaXL’s website claims that it relieves joint pain due to inflammation are disease-treatment claims, making it an unapproved new drug.

    section 201(g)(1)(B) and 201(p) of the Act [21 U.S.C. 321(g)(1)(B), 321(p)]; sections 301(d) and 505(a) [21 U.S.C. 331(d), 355(a)]
  3. FDA says ProbioticXL’s claims that it reduces cardiovascular disease risk factors, especially in smokers, are unauthorized health claims that make it a misbranded food.

    section 403(r)(1)(B) of the Act [21 U.S.C. 343(r)(1)(B)]

What FDA wants

FDA asks the company to notify it in writing within 15 working days of the specific steps taken to address the violations, prevent recurrence, and include related documents; if corrective actions cannot be completed in that time, the company must explain the delay and when it will finish.

Who should pay attention

  • probiotic and omega product brands
  • companies with disease-related claims on product websites
  • marketing and regulatory reviewers of online product claims

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Natuzem

    FDA warned Mexico-based Natuzem for selling unapproved new drugs, including Reumofan Plus, to U.S. consumers online.

    High risk
  2. RonanRx, Inc. dba RonanRx

    FDA says RonanRx's website and X posts misbrand compounded semaglutide and tirzepatide with false or misleading claims.

    Low
  3. Calibrate IV Hydration

    FDA told Calibrate IV Hydration its umbilical cord and exosome IV products are unapproved drugs and unlicensed biologics.

    High risk
  4. Best Chinese Medicines LLC

    FDA warned Best Chinese Medicines LLC that five herbal products sold online are unapproved new drugs because their labeling claims to treat diseases.

    High risk